دورية أكاديمية
أعرض في EDS

Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.

التفاصيل البيبلوغرافية
العنوان: Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
المؤلفون: Nguyen DT; The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam., Tran TTT; Oxford University Clinical Research Unit, Wellcome Trust Asia Programme, The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam., Nghiem NM; The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam., Le PT; The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam., Vo QM; The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam., Day J; Oxford University Clinical Research Unit, Wellcome Trust Asia Programme, The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom., Rahman M; Oxford University Clinical Research Unit, Wellcome Trust Asia Programme, The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom., Le HM; The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.
المصدر: PloS one [PLoS One] 2020 May 20; Vol. 15 (5), pp. e0233446. Date of Electronic Publication: 2020 May 20 (Print Publication: 2020).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Genotype*, Hepacivirus/*genetics , Hepatitis C, Chronic/*drug therapy , Sofosbuvir/*administration & dosage, Antiviral Agents/therapeutic use ; Benzimidazoles/therapeutic use ; Fluorenes/therapeutic use ; Hepacivirus/drug effects ; Humans ; Middle Aged ; Retrospective Studies ; Ribavirin/therapeutic use ; Treatment Outcome ; Uridine Monophosphate/analogs & derivatives ; Uridine Monophosphate/therapeutic use ; Vietnam ; Viral Load/drug effects ; Viral Load/genetics
مستخلص: Background: Hepatitis C virus (HCV) genotype 6 is the commonest cause of chronic hepatitis C infection in much of southeast Asia, but data on the effectiveness of direct-acting antiviral agents (DAAs) against this genotype are limited. We conducted a retrospective cohort study of patients attending the Hospital for Tropical Diseases (HTD), Ho Chi Minh City, Vietnam, to define the effectiveness of DAAs in the treatment of chronic HCV genotype 6 in actual practice.
Methods: We included all patients with genotype 6 infections attending our hospital between March 2016 and October 2017 who received treatment with sofosbuvir-based DAA treatment regimens, and compared their responses with those with genotype 1 infections.
Results: 1758 patients (1148 genotype 6, 65.4%; 610 genotype 1, 34.6%) were analyzed. The majority of patients (1480, 84.2%) received sofosbuvir/ledipasvir (SOF/LDV) ± ribavirin (RBV); 278 (15.8%) received sofosbuvir/Daclatasvir (SOF/DCV) ± RBV. The median age of the patients was 57 years, (interquartile range (IQR) 46-64 years) The baseline HCV viral load (log IU/ml) was significantly higher in patients infected with genotype 6 compared with those infected with genotype 1 (6.8, 5.3-6.6 versus 6.3, 5.3-6.5 log10 IU/ml, p = <0.001, Mann Whitney U test). A sustained virological response (SVR), defined as an undetectable viral load measured between 12 and 24 weeks after completing treatment, and indicating cure, was seen in 97.3% (1711/1758) of patients. Treatment failure, defined as HCV viral load ≥15 IU/ml ≥12 weeks after completing treatment appeared to be more frequent in patients infected with genotype 6 virus (3.2%, 37/1148) than in those infected with genotype 1 (1.7%, 10/610), p = 0.050 chi-squared test). We found no evidence that patient's age, gender, liver cirrhosis, diabetes, HBV or HIV coinfection, prior treatment failure with pegylated interferon therapy, body mass index (BMI), aspartate aminotransferase to platelet ratio index (APRI), or fibrosis 4 (FIB-4) index were associated with treatment failure.
Conclusions: Our study suggests that patients with HCV genotype 6 infection in Vietnam may respond less well to treatment with sofosbuvir based DAAs than patients with genotype 1 infections. Further studies are needed to confirm this observation and to define whether it is driven by genotype-specific mutations.
Competing Interests: The authors have declared that no competing interests exist.
References: PLoS One. 2018 Jun 28;13(6):e0199760. (PMID: 29953518)
Am J Gastroenterol. 2015 Aug;110(8):1179-85. (PMID: 26215530)
Liver Int. 2011 Jul;31 Suppl 2:61-80. (PMID: 21651703)
N Engl J Med. 2014 May 22;370(21):1993-2001. (PMID: 24795201)
Antivir Ther. 2018;23(5):415-423. (PMID: 29303482)
Virology. 2014 Nov;468-470:197-206. (PMID: 25193655)
Sci Rep. 2016 Feb 04;6:20310. (PMID: 26842909)
Gut. 2017 Oct;66(10):1844-1852. (PMID: 27418632)
Gastroenterology. 2015 Nov;149(6):1454-1461.e1. (PMID: 26261007)
Hepatology. 2015 Jan;61(1):77-87. (PMID: 25069599)
J Hepatol. 2016 Sep;65(3):473-82. (PMID: 27085252)
Antivir Ther. 2017;22(6):481-493. (PMID: 27934775)
Emerg Microbes Infect. 2017 Nov 1;6(11):e95. (PMID: 29089588)
N Engl J Med. 2015 Dec 31;373(27):2599-607. (PMID: 26571066)
J Hepatol. 2018 Aug;69(2):461-511. (PMID: 29650333)
Gastroenterology. 2016 Feb;150(2):419-29. (PMID: 26497081)
Aliment Pharmacol Ther. 2016 Jan;43(1):96-101. (PMID: 26503414)
Antimicrob Agents Chemother. 2016 Jan 11;60(3):1847-1853. (PMID: 26824950)
Drug Des Devel Ther. 2016 Aug 25;10:2659-67. (PMID: 27601883)
N Engl J Med. 2013 May 16;368(20):1878-87. (PMID: 23607594)
N Engl J Med. 2017 Jun 1;376(22):2134-2146. (PMID: 28564569)
Hepatology. 2011 May;53(5):1742-51. (PMID: 21374691)
PLoS One. 2019 Mar 13;14(3):e0212734. (PMID: 30865664)
Clin Infect Dis. 2018 Oct 30;67(10):1477-1492. (PMID: 30215672)
J Viral Hepat. 2017 Nov;24(11):927-935. (PMID: 28475232)
Hepatol Int. 2016 Sep;10(5):702-26. (PMID: 27130427)
J Viral Hepat. 2014 Dec;21(12):917-20. (PMID: 25131445)
المشرفين على المادة: 0 (Antiviral Agents)
0 (Benzimidazoles)
0 (Fluorenes)
0 (ledipasvir, sofosbuvir drug combination)
49717AWG6K (Ribavirin)
E2OU15WN0N (Uridine Monophosphate)
WJ6CA3ZU8B (Sofosbuvir)
تواريخ الأحداث: Date Created: 20200521 Date Completed: 20200820 Latest Revision: 20200820
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7239434
DOI: 10.1371/journal.pone.0233446
PMID: 32433676
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0233446